Institution
Fred Hutchinson Cancer Research Center
Nonprofit•Cape Town, South Africa•
About: Fred Hutchinson Cancer Research Center is a nonprofit organization based out in Cape Town, South Africa. It is known for research contribution in the topics: Population & Transplantation. The organization has 12322 authors who have published 30954 publications receiving 2288772 citations. The organization is also known as: Fred Hutch & The Hutch.
Topics: Population, Transplantation, Cancer, Breast cancer, Prostate cancer
Papers published on a yearly basis
Papers
More filters
••
University of Washington1, Fred Hutchinson Cancer Research Center2, American College of Surgeons3, University of Michigan4, Johns Hopkins University5, Mayo Clinic6, University of Texas MD Anderson Cancer Center7, University of California, San Francisco8, University at Buffalo9, Seattle Cancer Care Alliance10, University of South Florida11, Harvard University12
TL;DR: Although the majority of patients with MCC in this nationwide cohort did not undergo pathologic nodal evaluation, this procedure may be indicated in many cases as it improves prognostic accuracy and has important treatment implications for those found to have microscopic nodal involvement.
Abstract: Background The management of Merkel cell carcinoma (MCC) has been complicated by a lack of detailed prognostic data and by the presence of conflicting staging systems. Objective We sought to determine the prognostic significance of tumor size, clinical versus pathologic nodal evaluation, and extent of disease at presentation and thereby derive the first consensus staging/prognostic system for MCC. Methods A total of 5823 prospectively enrolled MCC cases from the National Cancer Data Base had follow-up data (median 64 months) and were used for prognostic analyses. Results At 5 years, overall survival was 40% and relative survival (compared with age- and sex-matched population data) was 54%. Among all MCC cases, 66% presented with local, 27% with nodal, and 7% with distant metastatic disease. For cases presenting with local disease only, smaller tumor size was associated with better survival (stage I, ≤2 cm, 66% relative survival at 5 years; stage II, >2 cm, 51%; P Limitations The National Cancer Data Base does not capture disease-specific survival. Overall survival for patients with MCC was therefore used to calculate relative survival based on matched population data. Conclusion Although the majority (68%) of patients with MCC in this nationwide cohort did not undergo pathologic nodal evaluation, this procedure may be indicated in many cases as it improves prognostic accuracy and has important treatment implications for those found to have microscopic nodal involvement.
446 citations
••
TL;DR: It is shown that Isw2 repositions nucleosomes to enforce directionality on transcription by preventing transcription initiation from cryptic sites, revealing how chromatin is organized on a global scale and advance the understanding of how transcription is regulated.
Abstract: Chromatin allows the eukaryotic cell to package its DNA efficiently. To understand how chromatin structure is controlled across the Saccharomyces cerevisiae genome, we have investigated the role of the ATP-dependent chromatin remodelling complex Isw2 in positioning nucleosomes. We find that Isw2 functions adjacent to promoter regions where it repositions nucleosomes at the interface between genic and intergenic sequences. Nucleosome repositioning by Isw2 is directional and results in increased nucleosome occupancy of the intergenic region. Loss of Isw2 activity leads to inappropriate transcription, resulting in the generation of both coding and noncoding transcripts. Here we show that Isw2 repositions nucleosomes to enforce directionality on transcription by preventing transcription initiation from cryptic sites. Our analyses reveal how chromatin is organized on a global scale and advance our understanding of how transcription is regulated.
445 citations
••
University of California, Los Angeles1, University of Pittsburgh2, Fred Hutchinson Cancer Research Center3, Stanford University4, Harvard University5, University of Cincinnati6, University of Massachusetts Boston7, Stony Brook University8, University of Wisconsin-Madison9, Baylor College of Medicine10, University of Texas Health Science Center at San Antonio11, Wayne State University12, University of Texas MD Anderson Cancer Center13, Yeshiva University14, University of California, Davis15
TL;DR: The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography.
Abstract: We analyzed the results of the WHI randomized clinical trial — in which one study group received 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate daily and another group received placebo — and examined temporal trends in breast-cancer diagnoses in the WHI observational-study cohort. Risk factors for breast cancer, frequency of mammography, and time-specific incidence of breast cancer were assessed in relation to combined hormone use. Results In the clinical trial, there were fewer breast-cancer diagnoses in the group receiving estrogen plus progestin than in the placebo group in the initial 2 years of the study, but the number of diagnoses increased over the course of the 5.6-year intervention period. The elevated risk decreased rapidly after both groups stopped taking the study pills, despite a similar frequency of mammography. In the observational study, the incidence of breast cancer was initially about two times as high in the group receiving menopausal hormones as in the placebo group, but this difference in incidence decreased rapidly in about 2 years, coinciding with year-to-year reductions in combined hormone use. During this period, differences in the frequency of mammography between the two groups were unchanged. Conclusions The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography.
445 citations
••
University of Washington1, Stanford University2, Pennsylvania State University3, University of California, San Diego4, Cold Spring Harbor Laboratory5, Florida State University6, Fred Hutchinson Cancer Research Center7, Yale University8, California Institute of Technology9, University of Massachusetts Medical School10, Duke University11, Emory University12, Children's Hospital of Philadelphia13, University of California, Irvine14, University of California, Santa Cruz15, National Institutes of Health16
TL;DR: The Mouse E NCODE Consortium is applying the same experimental pipelines developed for human ENCODE to annotate the mouse genome to enable a broad range of mouse genomics efforts.
Abstract: To complement the human Encyclopedia of DNA Elements (ENCODE) project and to enable a broad range of mouse genomics efforts, the Mouse ENCODE Consortium is applying the same experimental pipelines developed for human ENCODE to annotate the mouse genome
445 citations
••
Cambridge University Hospitals NHS Foundation Trust1, University of Cincinnati2, University of Lyon3, Southampton General Hospital4, Katholieke Universiteit Leuven5, University of Pittsburgh6, Cedars-Sinai Medical Center7, Autonomous University of Barcelona8, Columbia University9, University of Alabama at Birmingham10, VU University Medical Center11, University of Massachusetts Medical School12, McMaster University13, University of Verona14, Fred Hutchinson Cancer Research Center15, Paris Descartes University16, Royal North Shore Hospital17, Columbia University Medical Center18
TL;DR: It is demonstrated that obesity is not protective against fracture in postmenopausal women and is associated with increased risk of ankle and upper leg fractures.
444 citations
Authors
Showing all 12368 results
Name | H-index | Papers | Citations |
---|---|---|---|
Walter C. Willett | 334 | 2399 | 413322 |
Robert Langer | 281 | 2324 | 326306 |
Meir J. Stampfer | 277 | 1414 | 283776 |
JoAnn E. Manson | 270 | 1819 | 258509 |
David J. Hunter | 213 | 1836 | 207050 |
Peer Bork | 206 | 697 | 245427 |
Eric Boerwinkle | 183 | 1321 | 170971 |
Ruedi Aebersold | 182 | 879 | 141881 |
Bruce M. Psaty | 181 | 1205 | 138244 |
Aaron R. Folsom | 181 | 1118 | 134044 |
David Baker | 173 | 1226 | 109377 |
Frederick W. Alt | 171 | 577 | 95573 |
Lily Yeh Jan | 162 | 467 | 73655 |
Yuh Nung Jan | 162 | 460 | 74818 |
Charles N. Serhan | 158 | 728 | 84810 |